{"clinical_study": {"@rank": "54", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04280588"}, "id_info": {"org_study_id": "MRCTA, ECFAH of FMU [2020]027", "nct_id": "NCT04280588"}, "brief_title": "Fingolimod in COVID-19", "official_title": "Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)", "sponsors": {"lead_sponsor": {"agency": "First Affiliated Hospital of Fujian Medical University", "agency_class": "Other"}}, "source": "First Affiliated Hospital of Fujian Medical University", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2\n      pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane\n      formation, timely and appropriate use of immune modulator together with ventilator support\n      should be considered for the severe patients to prevent ARDS development. The\n      sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology\n      modulator which has been widely used in multiple sclerosis.The aim of this study was to\n      determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19)."}, "overall_status": "Recruiting", "start_date": {"@type": "Anticipated", "#text": "February 22, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "July 1, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "July 1, 2020"}, "phase": "Phase 2", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Non-Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": {"measure": "The change of pneumonia severity on X-ray images", "time_frame": "5 day after fingolimod treatment", "description": "The lesion change on X-ray images from day 5 to baseline"}, "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "30"}, "condition": "Coronavirus Disease (COVID-19)", "arm_group": [{"arm_group_label": "Treatment group", "arm_group_type": "Experimental"}, {"arm_group_label": "Control group", "arm_group_type": "No Intervention"}], "intervention": {"intervention_type": "Drug", "intervention_name": "Fingolimod 0.5 mg", "description": "Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days", "arm_group_label": "Treatment group"}, "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  The patients who were diagnosed with the common type of NCP (including severe risk\n             factors) and severe cases of new coronavirus pneumonia;\n\n          -  Aged 18 to 85 years;\n\n          -  Patients or authorized family members volunteered to participate in this study and\n             signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients with any history of bradyarrhythmia or atrioventricular blocks\n\n          -  Patients who are participating in other drug clinical trials;\n\n          -  Pregnant or lactating women;\n\n          -  ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50;\n\n          -  Definite diagnosis of rheumatic immune-related diseases;\n\n          -  Long-term oral anti-rejection or immunomodulatory drugs;\n\n          -  Patients with active pulmonary tuberculosis, with definite bacterial and fungal\n             infections."}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No"}, "overall_contact": {"last_name": "Ying Fu", "phone": "+86", "phone_ext": "+86", "email": "fuying1995@163.com"}, "location": {"facility": {"name": "Wan-Jin Chen", "address": {"city": "Fuzhou", "country": "China"}}, "status": "Recruiting", "contact": {"last_name": "Wan-Jin Chen, MD", "phone": "+1386061359", "phone_ext": "+1386061359", "email": "wanjinchen75@fjmu.edu.cn"}, "investigator": [{"last_name": "Ning Wang, MD", "role": "Principal Investigator"}, {"last_name": "Wan-Jin Chen, MD", "role": "Sub-Investigator"}]}, "location_countries": {"country": "China"}, "verification_date": "February 2020", "study_first_submitted": "February 20, 2020", "study_first_submitted_qc": "February 20, 2020", "study_first_posted": {"@type": "Actual", "#text": "February 21, 2020"}, "last_update_submitted": "February 20, 2020", "last_update_submitted_qc": "February 20, 2020", "last_update_posted": {"@type": "Actual", "#text": "February 21, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "First Affiliated Hospital of Fujian Medical University", "investigator_full_name": "Ning Wang, MD., PhD.", "investigator_title": "Doctor"}, "condition_browse": {"mesh_term": "Coronavirus Infections"}, "intervention_browse": {"mesh_term": "Fingolimod Hydrochloride"}, "patient_data": {"sharing_ipd": "Yes", "ipd_info_type": ["Study Protocol", "Statistical Analysis Plan (SAP)", "Informed Consent Form (ICF)", "Clinical Study Report (CSR)", "Analytic Code"]}}}